The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Houston

TX, USA. Electronic address:

[email]@mdanderson.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:. 2000 - 2012
  • Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. 2003 - 2012
  • Departments of Leukemia, Bioimmunotherapy, Biostatistics, and Blood and Bone Marrow Transplantation, USA. 2000

References

  1. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Kantarjian, H., Faderl, S., Garcia-Manero, G., Luger, S., Venugopal, P., Maness, L., Wetzler, M., Coutre, S., Stock, W., Claxton, D., Goldberg, S.L., Arellano, M., Strickland, S.A., Seiter, K., Schiller, G., Jabbour, E., Chiao, J., Plunkett, W. Lancet Oncol. (2012) [Pubmed]
  2. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Kantarjian, H.M., Thomas, X.G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.P., Chou, W.C., Buckstein, R., Cermak, J., Kuo, C.Y., Oriol, A., Ravandi, F., Faderl, S., Delaunay, J., Lysák, D., Minden, M., Arthur, C. J. Clin. Oncol. (2012) [Pubmed]
  3. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Kantarjian, H., O'Brien, S., Garcia-Manero, G., Faderl, S., Ravandi, F., Jabbour, E., Shan, J., Cortes, J. Cancer (2012) [Pubmed]
  4. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Kantarjian, H.M., Padmanabhan, S., Stock, W., Tallman, M.S., Curt, G.A., Li, J., Osmukhina, A., Wu, K., Huszar, D., Borthukar, G., Faderl, S., Garcia-Manero, G., Kadia, T., Sankhala, K., Odenike, O., Altman, J.K., Minden, M. Invest. New. Drugs (2011) [Pubmed]
  5. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Kantarjian, H., O'Brien, S., Jabbour, E., Shan, J., Ravandi, F., Kadia, T., Faderl, S., Garcia-Manero, G., Borthakur, G., Cortes, J. J. Clin. Oncol. (2011) [Pubmed]
  6. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Kantarjian, H.M., Giles, F.J., Bhalla, K.N., Pinilla-Ibarz, J., Larson, R.A., Gattermann, N., Ottmann, O.G., Hochhaus, A., Radich, J.P., Saglio, G., Hughes, T.P., Martinelli, G., Kim, D.W., Shou, Y., Gallagher, N.J., Blakesley, R., Baccarani, M., Cortes, J., le Coutre, P.D. Blood (2011) [Pubmed]
  7. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Kantarjian, H.M., Baccarani, M., Jabbour, E., Saglio, G., Cortes, J.E. Clin. Cancer Res. (2011) [Pubmed]
  8. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Kantarjian, H.M., Giles, F.J., Greenberg, P.L., Paquette, R.L., Wang, E.S., Gabrilove, J.L., Garcia-Manero, G., Hu, K., Franklin, J.L., Berger, D.P. Blood (2010) [Pubmed]
  9. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. Kantarjian, H.M., Erba, H.P., Claxton, D., Arellano, M., Lyons, R.M., Kovascovics, T., Gabrilove, J., Craig, M., Douer, D., Maris, M., Petersdorf, S., Shami, P.J., Yeager, A.M., Eckert, S., Abichandani, R., Faderl, S. J. Clin. Oncol. (2010) [Pubmed]
  10. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. Kantarjian, H., Garcia-Manero, G., O'Brien, S., Faderl, S., Ravandi, F., Westwood, R., Green, S.R., Chiao, J.H., Boone, P.A., Cortes, J., Plunkett, W. J. Clin. Oncol. (2010) [Pubmed]
  11. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. Kantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., Nakamae, H., Huguet, F., Boqué, C., Chuah, C., Bleickardt, E., Bradley-Garelik, M.B., Zhu, C., Szatrowski, T., Shapiro, D., Baccarani, M. N. Engl. J. Med. (2010) [Pubmed]
  12. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Kantarjian, H., Ravandi, F., O'Brien, S., Cortes, J., Faderl, S., Garcia-Manero, G., Jabbour, E., Wierda, W., Kadia, T., Pierce, S., Shan, J., Keating, M., Freireich, E.J. Blood (2010) [Pubmed]
  13. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. Kantarjian, H., Fenaux, P., Sekeres, M.A., Becker, P.S., Boruchov, A., Bowen, D., Hellstrom-Lindberg, E., Larson, R.A., Lyons, R.M., Muus, P., Shammo, J., Siegel, R., Hu, K., Franklin, J., Berger, D.P. J. Clin. Oncol. (2010) [Pubmed]
  14. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Kantarjian, H.M., Thomas, D., Ravandi, F., Faderl, S., Garcia-Manero, G., Shan, J., Pierce, S., Cortes, J., O'Brien, S. Leuk. Lymphoma (2010) [Pubmed]
  15. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Kantarjian, H.M., Thomas, D., Ravandi, F., Faderl, S., Jabbour, E., Garcia-Manero, G., Pierce, S., Shan, J., Cortes, J., O'Brien, S. Cancer (2010) [Pubmed]
  16. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Kantarjian, H., O'Brien, S., Ravandi, F., Borthakur, G., Faderl, S., Bueso-Ramos, C., Abruzzo, L., Pierce, S., Shan, J., Issa, J.P., Garcia-Manero, G. Cancer (2009) [Pubmed]
  17. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. Kantarjian, H.M., Shan, J., Jones, D., O'Brien, S., Rios, M.B., Jabbour, E., Cortes, J. J. Clin. Oncol. (2009) [Pubmed]
  18. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Kantarjian, H.M., Larson, R.A., Guilhot, F., O'Brien, S.G., Mone, M., Rudoltz, M., Krahnke, T., Cortes, J., Druker, B.J. Cancer (2009) [Pubmed]
  19. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Kantarjian, H., Cortes, J., Kim, D.W., Dorlhiac-Llacer, P., Pasquini, R., DiPersio, J., Müller, M.C., Radich, J.P., Khoury, H.J., Khoroshko, N., Bradley-Garelik, M.B., Zhu, C., Tallman, M.S. Blood (2009) [Pubmed]
  20. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Kantarjian, H., Pasquini, R., Lévy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., Hughes, T., Bleickardt, E., Dejardin, D., Cortes, J., Shah, N.P. Cancer (2009) [Pubmed]
  21. Introduction: targeting different pathways to prevent tumor cell development. Kantarjian, H.M. Semin. Oncol. (2009) [Pubmed]
  22. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Kantarjian, H., O'Brien, S., Shan, J., Huang, X., Garcia-Manero, G., Faderl, S., Ravandi-Kashani, F., Verstovsek, S., Beth Rios, M., Cortes, J. Cancer (2008) [Pubmed]
  23. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Kantarjian, H., Schiffer, C., Jones, D., Cortes, J. Blood (2008) [Pubmed]
  24. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Kantarjian, H., O'Brien, S., Cortes, J., Wierda, W., Faderl, S., Garcia-Manero, G., Issa, J.P., Estey, E., Keating, M., Freireich, E.J. Cancer (2008) [Pubmed]
  25. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Kantarjian, H., O'Brien, S., Ravandi, F., Cortes, J., Shan, J., Bennett, J.M., List, A., Fenaux, P., Sanz, G., Issa, J.P., Freireich, E.J., Garcia-Manero, G. Cancer (2008) [Pubmed]
  26. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Kantarjian, H., Giles, F., List, A., Lyons, R., Sekeres, M.A., Pierce, S., Deuson, R., Leveque, J. Cancer (2007) [Pubmed]
  27. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Kantarjian, H.M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G.J., Nicolini, F.E., O'Brien, S.G., Litzow, M., Bhatia, R., Cervantes, F., Haque, A., Shou, Y., Resta, D.J., Weitzman, A., Hochhaus, A., le Coutre, P. Blood (2007) [Pubmed]
  28. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Kantarjian, H.M., O'Brien, S., Huang, X., Garcia-Manero, G., Ravandi, F., Cortes, J., Shan, J., Davisson, J., Bueso-Ramos, C.E., Issa, J.P. Cancer (2007) [Pubmed]
  29. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., Robak, T., Khoroshko, N., Masszi, T., Skotnicki, A., Hellmann, A., Zaritsky, A., Golenkov, A., Radich, J., Hughes, T., Countouriotis, A., Shah, N. Blood (2007) [Pubmed]
  30. Important therapeutic targets in chronic myelogenous leukemia. Kantarjian, H.M., Giles, F., Quintás-Cardama, A., Cortes, J. Clin. Cancer Res. (2007) [Pubmed]
  31. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Kantarjian, H., O'Brien, S., Talpaz, M., Borthakur, G., Ravandi, F., Faderl, S., Verstovsek, S., Rios, M.B., Shan, J., Giles, F., Cortes, J. Cancer (2007) [Pubmed]
  32. Clofarabine: past, present, and future. Kantarjian, H.M., Jeha, S., Gandhi, V., Wess, M., Faderl, S. Leuk. Lymphoma (2007) [Pubmed]
  33. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Kantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., Ferrajoli, A., Wierda, W., Shan, J., Davis, J., Giles, F., Saba, H.I., Issa, J.P. Blood (2007) [Pubmed]
  34. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Kantarjian, H.M., O'Brien, S., Shan, J., Aribi, A., Garcia-Manero, G., Jabbour, E., Ravandi, F., Cortes, J., Davisson, J., Issa, J.P. Cancer (2007) [Pubmed]
  35. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Kantarjian, H.M., Cortes, J., Guilhot, F., Hochhaus, A., Baccarani, M., Lokey, L. Cancer (2007) [Pubmed]
  36. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Kantarjian, H., O'brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia-Manero, G., Wierda, W., Pierce, S., Shan, J., Estey, E. Cancer (2006) [Pubmed]
  37. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Kantarjian, H., Beran, M., Cortes, J., O'Brien, S., Giles, F., Pierce, S., Shan, J., Plunkett, W., Keating, M., Estey, E. Cancer (2006) [Pubmed]
  38. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Kantarjian, H., Issa, J.P., Rosenfeld, C.S., Bennett, J.M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., Helmer, R., Shen, L., Nimer, S.D., Leavitt, R., Raza, A., Saba, H. Cancer (2006) [Pubmed]
  39. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Kantarjian, H.M., Talpaz, M., O'Brien, S., Jones, D., Giles, F., Garcia-Manero, G., Faderl, S., Ravandi, F., Rios, M.B., Shan, J., Cortes, J. Blood (2006) [Pubmed]
  40. New strategies in chronic myeloid leukemia. Kantarjian, H.M., Cortes, J. Int. J. Hematol. (2006) [Pubmed]
  41. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Hochhaus, A., Griffin, J.D., Hoelzer, D., Albitar, M., Dugan, M., Cortes, J., Alland, L., Ottmann, O.G. N. Engl. J. Med. (2006) [Pubmed]
  42. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Kantarjian, H.M., Talpaz, M., Giles, F., O'Brien, S., Cortes, J. Ann. Intern. Med. (2006) [Pubmed]
  43. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Kantarjian, H., Talpaz, M., O'Brien, S., Giles, F., Faderl, S., Verstovsek, S., Garcia-Manero, G., Shan, J., Rios, M.B., Champlin, R., de Lima, M., Cortes, J. Cancer (2005) [Pubmed]
  44. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Kantarjian, H.M., Bueso-Ramos, C.E., Talpaz, M., O'Brien, S., Giles, F., Faderl, S., Wierda, W., Rios, M.B., Shan, J., Cortes, J. Cancer (2005) [Pubmed]
  45. Decitabine dosing schedules. Kantarjian, H.M., Issa, J.P. Semin. Hematol. (2005) [Pubmed]
  46. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Kantarjian, H.M., Bueso-Ramos, C.E., Talpaz, M., O'Brien, S., Giles, F., Rios, M.B., Shan, J., Cortes, J. Leuk. Lymphoma (2005) [Pubmed]
  47. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Shan, J., Rios, M.B., Faderl, S., Verstovsek, S., Garcia-Manero, G., Wierda, W., Kornblau, S., Ferrajoli, A., Keating, M., Talpaz, M. Clin. Cancer Res. (2004) [Pubmed]
  48. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Giles, F., Rios, M.B., Shan, J., Letvak, L., Thomas, D., Faderl, S., Ferrajoli, A., Cortes, J. Blood (2004) [Pubmed]
  49. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Kantarjian, H.M., Cortes, J.E., O'Brien, S., Luthra, R., Giles, F., Verstovsek, S., Faderl, S., Thomas, D., Garcia-Manero, G., Rios, M.B., Shan, J., Jones, D., Talpaz, M. Blood (2004) [Pubmed]
  50. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Kantarjian, H., Thomas, D., O'Brien, S., Cortes, J., Giles, F., Jeha, S., Bueso-Ramos, C.E., Pierce, S., Shan, J., Koller, C., Beran, M., Keating, M., Freireich, E.J. Cancer (2004) [Pubmed]
  51. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Kantarjian, H.M., Cortes, J.E., O'Brien, S., Giles, F., Garcia-Manero, G., Faderl, S., Thomas, D., Jeha, S., Rios, M.B., Letvak, L., Bochinski, K., Arlinghaus, R., Talpaz, M. Blood (2003) [Pubmed]
  52. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Kantarjian, H.M., Talpaz, M., Cortes, J., O'Brien, S., Faderl, S., Thomas, D., Giles, F., Rios, M.B., Shan, J., Arlinghaus, R. Clin. Cancer Res. (2003) [Pubmed]
  53. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Kantarjian, H.M., O'Brien, S., Cortes, J.E., Shan, J., Giles, F.J., Rios, M.B., Faderl, S.H., Wierda, W.G., Ferrajoli, A., Verstovsek, S., Keating, M.J., Freireich, E.J., Talpaz, M. Cancer (2003) [Pubmed]
  54. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. Kantarjian, H.M., Gandhi, V., Kozuch, P., Faderl, S., Giles, F., Cortes, J., O'Brien, S., Ibrahim, N., Khuri, F., Du, M., Rios, M.B., Jeha, S., McLaughlin, P., Plunkett, W., Keating, M. J. Clin. Oncol. (2003) [Pubmed]
  55. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Kantarjian, H., Talpaz, M., O'Brien, S., Giles, F., Rios, M.B., White, K., Garcia-Manero, G., Ferrajoli, A., Verstovsek, S., Wierda, W., Kornblau, S., Cortes, J. Cancer (2003) [Pubmed]
  56. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Kantarjian, H., Gandhi, V., Cortes, J., Verstovsek, S., Du, M., Garcia-Manero, G., Giles, F., Faderl, S., O'Brien, S., Jeha, S., Davis, J., Shaked, Z., Craig, A., Keating, M., Plunkett, W., Freireich, E.J. Blood (2003) [Pubmed]
  57. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Thomas, D., Kornblau, S., Shan, J., Beth Rios, M., Keating, M., Freireich, E., Talpaz, M. Cancer (2003) [Pubmed]
  58. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Garcia-Manero, G., Faderl, S., O'Brien, S., Cortes, J., Talpaz, M., Kantarjian, H.M. Cancer (2003) [Pubmed]
  59. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Kantarjian, H.M., O'Brien, S., Cortes, J., Giles, F.J., Faderl, S., Issa, J.P., Garcia-Manero, G., Rios, M.B., Shan, J., Andreeff, M., Keating, M., Talpaz, M. Cancer (2003) [Pubmed]
  60. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cortes, J., Talpaz, M., O'Brien, S., Giles, F., Beth Rios, M., Shan, J., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Kantarjian, H. Cancer (2003) [Pubmed]
  61. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Kantarjian, H., O'Brien, S., Cortes, J., Shan, J., Giles, F., Garcia-Manero, G., Verstovsek, S., Faderl, S., Rios, M.B., Talpaz, M. Cancer (2003) [Pubmed]
  62. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Kantarjian, H.M., O'Brien, S., Cortes, J., Giles, F.J., Rios, M.B., Shan, J., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Verstovsek, S., Wierda, W., Keating, M., Talpaz, M. Cancer (2003) [Pubmed]
  63. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., Druker, B., Goldman, J., O'Brien, S.G., Russell, N., Fischer, T., Ottmann, O., Cony-Makhoul, P., Facon, T., Stone, R., Miller, C., Tallman, M., Brown, R., Schuster, M., Loughran, T., Gratwohl, A., Mandelli, F., Saglio, G., Lazzarino, M., Russo, D., Baccarani, M., Morra, E. N. Engl. J. Med. (2002) [Pubmed]
  64. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Kantarjian, H.M., Cortes, J., O'Brien, S., Giles, F.J., Albitar, M., Rios, M.B., Shan, J., Faderl, S., Garcia-Manero, G., Thomas, D.A., Resta, D., Talpaz, M. Blood (2002) [Pubmed]
  65. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Kantarjian, H.M., O'Brien, S., Cortes, J.E., Smith, T.L., Rios, M.B., Shan, J., Yang, Y., Giles, F.J., Thomas, D.A., Faderl, S., Garcia-Manero, G., Jeha, S., Wierda, W., Issa, J.P., Kornblau, S.M., Keating, M., Resta, D., Capdeville, R., Talpaz, M. Clin. Cancer Res. (2002) [Pubmed]
  66. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Kantarjian, H.M., Talpaz, M., O'Brien, S., Smith, T.L., Giles, F.J., Faderl, S., Thomas, D.A., Garcia-Manero, G., Issa, J.P., Andreeff, M., Kornblau, S.M., Koller, C., Beran, M., Keating, M., Rios, M.B., Shan, J., Resta, D., Capdeville, R., Hayes, K., Albitar, M., Freireich, E.J., Cortes, J.E. Clin. Cancer Res. (2002) [Pubmed]
  67. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Kantarjian, H.M., O'Brien, S., Cortes, J.E., Giralt, S.A., Rios, M.B., Shan, J., Giles, F.J., Thomas, D.A., Faderl, S., De Lima, M., Garcia-Manero, G., Champlin, R., Arlinghaus, R., Talpaz, M. Blood (2002) [Pubmed]
  68. Adult acute lymphocytic leukemia. Future research directions. Kantarjian, H.M. Hematol. Oncol. Clin. North Am. (2001) [Pubmed]
  69. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Kantarjian, H.M., Shan, J., Smith, T., Talpaz, M., Kozuch, P., Rios, M.B., Cortes, J., Giles, F.J., O'Brien, S. Cancer (2001) [Pubmed]
  70. Homoharringtonine: history, current research, and future direction. Kantarjian, H.M., Talpaz, M., Santini, V., Murgo, A., Cheson, B., O'Brien, S.M. Cancer (2001) [Pubmed]
  71. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. Kantarjian, H.M., Talpaz, M., Smith, T.L., Cortes, J., Giles, F.J., Rios, M.B., Mallard, S., Gajewski, J., Murgo, A., Cheson, B., O'Brien, S. J. Clin. Oncol. (2000) [Pubmed]
  72. Therapeutic choices in younger patients with chronic myelogenous leukemia. Kantarjian, H.M., Giles, F.J., O'Brien, S., Giralt, S., Talpaz, M. Cancer (2000) [Pubmed]
  73. Adult acute lymphocytic leukemia. Introduction and questions related to current programs. Kantarjian, H.M. Hematol. Oncol. Clin. North Am. (2000) [Pubmed]
 
WikiGenes - Universities